Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the exciting new field of HER2-low breast cancer. The recent Phase III DESTINY-Breast04 (NCT03734029) trial investigated trastuzumab deruxtecan in HER2-low metastatic breast cancer patients (mBC), resulting in a positive progression-free survival (PFS) and overall-survival (OS), indicating future approval of trastuzumab deruxtecan for HER2-low mBC. Although this new subcategory of breast cancer could benefit a large population of patients, Dr Tarantino emphasizes there are still many aspects of HER2-low breast cancer which require elucidation. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

свернуть